These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22801991)

  • 21. Obesity, diabetes mellitus and last but not least, osteoporosis.
    Paula FJ; Rosen CJ
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):150-7. PubMed ID: 20485903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fat and bone interactions.
    Bermeo S; Gunaratnam K; Duque G
    Curr Osteoporos Rep; 2014 Jun; 12(2):235-42. PubMed ID: 24599601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
    Lomonaco R; Ortiz-Lopez C; Orsak B; Webb A; Hardies J; Darland C; Finch J; Gastaldelli A; Harrison S; Tio F; Cusi K
    Hepatology; 2012 May; 55(5):1389-97. PubMed ID: 22183689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome in childhood from impaired carbohydrate metabolism to nonalcoholic fatty liver disease.
    Manco M
    J Am Coll Nutr; 2011 Oct; 30(5):295-303. PubMed ID: 22081615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiorgan, Multimodality Imaging in Cardiometabolic Disease.
    Kumar V; Hsueh WA; Raman SV
    Circ Cardiovasc Imaging; 2017 Nov; 10(11):. PubMed ID: 29122843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic Syndrome and Bone: Pharmacologically Induced Diabetes has Deleterious Effect on Bone in Growing Obese Rats.
    Bagi CM; Edwards K; Berryman E
    Calcif Tissue Int; 2018 Jun; 102(6):683-694. PubMed ID: 29196931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease.
    Baranova A; Randhawa M; Jarrar M; Younossi ZM
    Expert Rev Mol Diagn; 2007 Mar; 7(2):195-205. PubMed ID: 17331066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome].
    Anty R; Gual P; Huet PM; Marchand-Brustel YL; Tran A
    Gastroenterol Clin Biol; 2007 Dec; 31(12):1127-34. PubMed ID: 18176372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reptin: a new therapeutic target for metabolic syndrome and fatty liver diseases].
    Javary J; Allain-Courtois N; Benhamouche-Trouillet S
    Med Sci (Paris); 2018; 34(8-9):637-639. PubMed ID: 30230463
    [No Abstract]   [Full Text] [Related]  

  • 30. Ghrelin and liver disease.
    Quiñones M; Fernø J; Al-Massadi O
    Rev Endocr Metab Disord; 2020 Mar; 21(1):45-56. PubMed ID: 31758299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology.
    Zhao J; Lei H; Wang T; Xiong X
    Front Endocrinol (Lausanne); 2023; 14():1161402. PubMed ID: 36967758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Metabolic syndrome: how about bone?].
    Hernández Hernández JL; Riancho Moral JA; González Macías J
    Med Clin (Barc); 2008 May; 130(19):745-50. PubMed ID: 18570802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interrelationships between hepatic fat and insulin resistance in non-alcoholic fatty liver disease.
    Lockman KA; Nyirenda MJ
    Curr Diabetes Rev; 2010 Sep; 6(5):341-7. PubMed ID: 20701585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The endocrine role of the skeleton: background and clinical evidence.
    Schwetz V; Pieber T; Obermayer-Pietsch B
    Eur J Endocrinol; 2012 Jun; 166(6):959-67. PubMed ID: 22436399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Insulin resistance in non-alcoholic fatty liver disease].
    Park JH
    Korean J Hepatol; 2006 Mar; 12(1):16-30. PubMed ID: 16565603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women.
    Moon SS; Lee YS; Kim SW
    Endocrine; 2012 Oct; 42(2):423-9. PubMed ID: 22407492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty acid transport proteins, implications in physiology and disease.
    Kazantzis M; Stahl A
    Biochim Biophys Acta; 2012 May; 1821(5):852-7. PubMed ID: 21979150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De novo lipogenesis in health and disease.
    Ameer F; Scandiuzzi L; Hasnain S; Kalbacher H; Zaidi N
    Metabolism; 2014 Jul; 63(7):895-902. PubMed ID: 24814684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling.
    Kaneko H; Anzai T; Nagai T; Anzai A; Takahashi T; Mano Y; Morimoto K; Maekawa Y; Itoh H; Yoshikawa T; Ogawa S; Fukuda K
    Cardiovasc Res; 2011 Aug; 91(3):546-55. PubMed ID: 21447704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.